Join
Live feed
·
INSIDERFilingvia Quantisnow
Inhibikase Therapeutics Inc. logo

President & Head of R&D Cabell Christopher returned 338,282 shares to the company, decreasing direct ownership by 33% to 676,564 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
IKT· Inhibikase Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IKT (Inhibikase Therapeutics Inc.) and more on Quantisnow.